NEW YORK (
) -- Bill Ackman's exit from
(JCP - Get Report)
board of directors isn't a death knell for activist investing.
Ackman's departure from J.C. Penney comes after his hand-picked CEO Ron Johnson failed to turn around the struggling retail giant, and the hedge funder waged a losing war over the company's management and strategy. Many now wonder whether J.C. Penney can make it past the holidays, after spending billions on a failed store revamp that drained the company's cash coffers.
J.C. Penney elected retail industry veteran Ronald W. Tysoe, the former vice chairman of what is now
, to the company's board on Tuesday, a move Ackman said he supports.
The hedge funder's retreat at J.C. Penney comes as his nemesis, Daniel Loeb of
Third Point Capital Management
, was forced by Hollywood icon George Clooney to backtrack from highly critical comments he made to
(SNE - Get Report)
management. Loeb owns about $1 billion in Sony shares and seeks to spin off the company's movie studio business in an attempt to revive the struggling electronics giant.
Carl C. Icahn, the dean of modern day activist investing, meanwhile, faces the imminent prospect of failing to win over
shareholders on a competing bid to what could be one of the biggest leveraged buyouts in history.
Ackman, Loeb and Icahn are all intimately connected to a drama at
. Ackman has bet $1 billion that the company is little more than a Ponzi scheme. Loeb and Icahn have publicly taken the other side of Ackman's trade and have, so far, made millions of dollars in profit. "New HLF product: The Herbalife Enema administered by Uncle Carl," Loeb wrote on his
profile in July.
Clearly, a crass breed of barbarians is storming the gates of Corporate America. What board would let them in?
The answer is that while Ackman, Loeb and Icahn may be pushing the limits of good judgment, they will continue to have a significant influence on markets.
Ackman, after all, remains an independent director on
board. Meanwhile, the hedge funder has recently made a play at chemicals giant
. Loeb can count a turnaround at
(YHOO - Get Report)
under new CEO Marissa Mayer as a major recent activist success.
Loeb, at times, resorted to crude tactics such as publicly shaming Yahoo!'s former CEO Scott Thompson. With hindsight, the company's shareholders are likely to view such actions as necessary.
Carl Icahn helped to pull
from the brink of bankruptcy after building an investor consortium on the embattled oil and gas driller's board. Analysts see Icahn's influence as helping impart Chesapeake's management change and its execution on needed asset sales and capital expenditure reductions.
Still, Ackman and Loeb are likely to consider recent setbacks at J.C. Penney and Sony as a learning experience. If either hedge fund manager considers changing their tactics, there are others to follow who play a less-heralded but similarly influential role on investments.
Jeffrey Ubben of
ValueAct Capital Management
, while generally media shy, may be the activist to watch
. Quietly, Ubben and ValueAct have won board seats and supported drastic changes at firms such as
that are paying off for shareholders.
ValueAct may be on the verge of its most impressive activist investments yet after taking a large position in
(MSFT - Get Report)
shares earlier in 2013. While Microsoft is the dominant player in PC-software, its earnings outlook has become clouded by a string of failed attempts to enter the smartphone and tablet markets.
in 2012 that he liked to work with management in so-called activist investments and has recently pushed for firms to consider
mergers and acquisitions
. Microsoft may presently be in need of a transformative acquisition and the company is consistently speculated as an acquirer.
In the health care sector, Larry Robbins of
operates in a similarly understated manner, even if the hedge funder has assembled a multi-billion dollar bet on the
consolidating health care sector
. On Monday, Glenview won a shareholder vote to take full control of
Health Management's Associates
board of directors as they seek a
higher share price
Community Health Management's
near $4 billion bid for the company.
Like Ubben, Robbins can be described as an "activist" investor; however, he prefers the notion of being a "suggestivist" who works with management in most cases. Shareholder votes such as the one conducted at Health Management on Monday indicate Robbins' style has a high degree of credibility with investors in the health care sector.